EX-23.1 3 tm238252d1_ex23-1.htm EXHIBIT 23.1

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

We consent to the use of our report dated March 9, 2023, with respect to the consolidated financial statements of Seelos Therapeutics, Inc., incorporated herein by reference.

 

/s/ KPMG LLP

 

Short Hills, New Jersey

March 9, 2023